EUVIMEDEUVIMED entdecken
Crossref

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay

Yi-An Bi, Samantha Jordan, Amanda King-Ahmad, Mark A West, Manthena V S Varma iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Yi-An Bi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C8, Drug Interactions, Hepatocytes, Liver-Specific Organic Anion Transporter 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daprodustat is the first oral hypoxia‐inducible factor prolyl hydroxylase inhibitor approved recently for the treatment of anemia caused by chronic kidney disease (CKD) in adults receiving dialysis. We evaluated the role of organic anion transporting polypeptide (OATP)1B‐mediated hepatic uptake transport in the pharmacokinetics (PKs) of daprodustat using in vitro and in vivo studies, and physiologically‐based PK (PBPK) modeling of its drug–drug interactions (DDIs) with inhibitor drugs. In vitro , daprodustat showed specific transport by OATP1B1/1B3 in the transfected cell systems and primary human and monkey hepatocytes. A single‐dose oral rifampin (OATP1B inhibitor) reduced daprodustat intravenous clearance by a notable 9.9 ± 1.2‐fold ( P < 0.05) in cynomolgus monkeys. Correspondingly, volume of distribution at steady‐state was also reduced by 5.0 ± 1.1‐fold, whereas the half‐life change was minimal (1.5‐fold), corroborating daprodustat hepatic uptake inhibition by rifampin. A PBPK model accounting for OATP1B‐CYP2C8 interplay was developed, which well described daprodustat PK and DDIs with gemfibrozil (CYP2C8 and OATP1B inhibitor) and trimethoprim (weak CYP2C8 inhibitor) within 25% error of the observed data in healthy subjects. About 18‐fold increase in daprodustat area under the curve (AUC) following gemfibrozil treatment was found to be associated with strong CYP2C8 inhibition and moderate OATP1B inhibition. Moreover, PK modulation in hepatic dysfunction and subjects with CKD, in comparison to healthy control, was well‐captured by the model. CYP2C8 and/or OATP1B inhibitor drugs (e.g., gemfibrozil, clopidogrel, rifampin, and cyclosporine) were predicted to perpetrate moderate‐to‐strong DDIs in healthy subjects, as well as, in target CKD population. Daprodustat can be used as a sensitive CYP2C8 index substrate in the absence of OATP1B modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C8Drug InteractionsHepatocytesLiver-Specific Organic Anion Transporter 1Renal Insufficiency, ChronicRifampinSolute Carrier Organic Anion Transporter Family Member 1B3AdultAnimalsFemaleHumansMaleCytochrome P-450 CYP2C8 InhibitorsGlycineHEK293 CellsLiver DiseasesMacaca fascicularisBarbiturates

Substanzen

Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C8 InhibitorsGlycineLiver-Specific Organic Anion Transporter 1RifampinSolute Carrier Organic Anion Transporter Family Member 1B3CYP2C8 protein, humanSLCO1B1 protein, humanSLCO1B3 protein, humanGSK1278863

Autor:innen und Institutionen

  • Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA.

ORCID-Profile: Manthena V S Varma

Zitieren

APA

Bi, Y. A., Jordan, S., King-Ahmad, A., West, M. A., & Varma, M. V. S. (2024). Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3215

Vancouver

Bi YA, Jordan S, King-Ahmad A, West MA, Varma MVS. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3215

BibTeX
@article{Bi2024,
  author = {Bi, Yi-An and Jordan, Samantha and King-Ahmad, Amanda and West, Mark A and Varma, Manthena V S},
  title = {Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3215}
}
Kostenlos starten →